| BCBS Highmark Delaware | Inebilizumab-cdon (Uplizna) | 2026-03-02 |
| BCBS Highmark Delaware | Chimeric Antigen Receptor T-Cell and T-Cell Receptor Therapies | 2026-03-02 |
| BCBS Highmark Delaware | Hemophilia Treatment Clotting Factors/Coagulant Blood Products | 2026-03-02 |
| BCBS Highmark Delaware | Denosumab (Prolia, Xgeva) and Denosumab Biosimilars | 2026-03-02 |
| BCBS Highmark Delaware | Amivantamab-vmjw (Rybrevant) and Amivantamab and Hyaluronidase-lpuj (Rybrevant Faspro) | 2026-03-02 |
| UHC Medicare Advantage | Gastroesophageal and Gastrointestinal (GI) Services and Procedures – Medicare Advantage Medical Policy | 2026-03-01 |
| UHC Medicare Advantage | Medications/Drugs (Outpatient/Part B) – Medicare Advantage Medical Policy | 2026-03-01 |
| UHC Medicare Advantage | Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease – Medicare Advantage Medical Policy | 2026-03-01 |
| UHC Medicare Advantage | Pharmacogenomics Testing – Medicare Advantage Medical Policy | 2026-03-01 |
| UHC Medicare Advantage | Radiation and Oncologic Procedures – Medicare Advantage Medical Policy | 2026-03-01 |